Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Fineline Cube Jul 17, 2026
Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Fineline Cube Jul 17, 2026
Legal / IP

China’s National People’s Congress Approves Stricter Punishments for Sector-Specific Bribery

Fineline Cube Jan 4, 2024

The 7th meeting of the 14th National People’s Congress Standing Committee has passed the latest...

Company Deals Legal / IP

Daiichi Sankyo and Esperion Therapeutics Amend Collaboration on Antilipidemic Drugs

Fineline Cube Jan 4, 2024

Daiichi Sankyo (TYO: 4568)’s European subsidiary, a Japanese pharmaceutical company, has entered into a collaboration...

Company Drug

Shanghai BDgene Technology’s Thalassemia Gene Therapy BD211 Clears NMPA for Clinical Trials

Fineline Cube Jan 4, 2024

Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has received clinical trial approval...

Company Drug

Belief BioMed Group Initiates Clinical Study for Hemophilia A Gene Therapy BBM-H803 in China

Fineline Cube Jan 4, 2024

Belief BioMed Group, a Shanghai-based gene therapy specialist, has announced the first subject dosing in...

Company Deals

IASO Biotherapeutics and Umoja Biopharma Join Forces for Innovative Cell and Gene Therapies Development

Fineline Cube Jan 4, 2024

IASO Biotherapeutics, a China-based company, and Umoja Biopharma, a California-headquartered developer of off-the-shelf cell therapies,...

Company Deals

Full-Life Technologies Secures USD 63.3 Million in Financing to Boost Radiotherapeutics Pipeline and Manufacturing

Fineline Cube Jan 4, 2024

Full-Life Technologies Ltd, a global radiotherapeutics company with a presence in Belgium, Germany, and China,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approval for Abiraterone in Prostate Cancer Treatment

Fineline Cube Jan 4, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing approval...

Company Drug

ImmunoTech Biopharm Commences Patient Enrollment in Phase II Study for CAR-T-19 Injection

Fineline Cube Jan 4, 2024

ImmunoTech Biopharm Ltd, a China-based specialist in chimeric antigen receptor T-cell (CAR-T) therapies (HKG: 6978),...

Company

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy

Fineline Cube Jan 4, 2024

Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the...

Company Deals

GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies

Fineline Cube Jan 4, 2024

GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...

Company Drug

Sino Biopharmaceutical Ltd Secures Exclusive Rights for Generic Everolimus in China

Fineline Cube Jan 4, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced that...

Company Deals

Kexing Pharmaceutical Enters Global Licensing Agreement with Xiling Lab for Eribulin Generic

Fineline Cube Jan 4, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with...

Company Deals

Bio-Thera Solutions Grants Macter International Exclusive Rights to Avzivi in Pakistan and Afghanistan

Fineline Cube Jan 4, 2024

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biopharmaceutical company, has announced a licensing and commercialization agreement...

Company Deals

Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH

Fineline Cube Jan 4, 2024

Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou...

Company Drug

Sciwind Biosciences’ Ecnolgutide Shows Promising Phase III Results in Type 2 Diabetes Treatment

Fineline Cube Jan 4, 2024

Sciwind Biosciences Co., Ltd, a China-based pharmaceutical company, has released the latest topline Phase III...

Company Deals

JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China

Fineline Cube Jan 3, 2024

JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...

Company Drug

InventisBio’s KRAS G12C Inhibitor Garsorasib NDA Accepted for Review by China’s NMPA

Fineline Cube Jan 3, 2024

InventisBio (Shanghai) Co., Ltd (SHA: 688382), a China-based pharmaceutical company, has announced that the New...

Company Deals

Frontage Laboratories Expands European Footprint with Acquisition of Accelera’s DMPK Businesses

Fineline Cube Jan 3, 2024

Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou,...

Company Drug

AstraZeneca and Sanofi’s RSV Prevention Drug Beyfortus Approved by China’s NMPA

Fineline Cube Jan 3, 2024

AstraZeneca (AZ, NASDAQ: AZN) and Sanofi (NASDAQ: SNY), co-development partners in the pharmaceutical industry, have...

Company Deals

China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease

Fineline Cube Jan 3, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend...

Posts pagination

1 … 451 452 453 … 696

Recent updates

  • CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer
  • CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma
  • Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
  • Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
  • Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.